Localisation of bevacizumab in the monkey retina after an intravitreal injection of Avastin;Lokalisation von Bevacizumab in der Netzhaut von Affen nach einer intravitrealen Bevacizumab-Injektion

Ophthalmologe

Volumn 106, Issue 7, 2009, Pages 619-624

  Schraermeyer, U ^a   Heiduschka, P ^a   Bartz Schmidt, K U ^b  

^a Sektion für experimentelle vitreoretinale Chirurgie   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antibody; Bevacizumab; Retina; Transport; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; INJECTION; MACACA; METABOLIC CLEARANCE RATE; METABOLISM; RETINA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DRUG SYNERGISM; INJECTIONS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; RETINA;

EID: 70349762202     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-008-1835-7     Document Type: Article

References (17)

1. Feiner L, Barr EE, Shui YB et al. (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26: 882-888.
2. Heiduschka P, Fietz H, Hofmeister S et al. (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814-2823.
3. Heiduschka P, Julien S, Hofmeister S et al. (2008) Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28: 46-55.
4. Inan UU, Avci B, Kusbeci T et al. (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773-1781.
5. Klettner A et al. (2007) DOG-Abstract SO.07.10; ePub ahead of Print bei IOVS).
6. Lüke M, Warga M, Ziemssen F et al. (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90: 1178-1182.
7. Manzano RPA, Peyman GA, Khan P et al. (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257-261.
8. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26: 270-274.
9. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536-544.
10. Moschos MM, Brouzas D, Apostolopoulos M et al. (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114: 37-44.
11. Pai SA, Shetty R, Vijayan PB et al. (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143: 601-606.
12. Peters S, Heiduschka P, Julien S et al. (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995-1002.
13. Schraermeyer U, Henke-Fahle S, Grisanti S et al. (2006) Evidence for transport of bevacizumab (Avastin) through the retina by Müller cells in rabbits. Invest Ophthalmol Vis Sci 47: E-Abstract 4169.
14. Shah MA, Ilson D, Kelsen DP (2005). Thrombembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23: 2574-2576.
15. Shahar J, Avery RL, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269.
16. Shetty R, Pai SA, Vincent A et al. (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116: 129-35.
17. Ziemssen F, Lüke M, Messias A et al. (2008) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28: 101-109.